Predictive role of EGFR mutation status on postoperative prognosis in patients with resected lung adenocarcinomas

Chinese Journal of Lung Cancer

Volumn 16, Issue 4, 2013, Pages 177-183

  Dong, Yu ^a   Li, Ying ^a   Peng, Hong ^a   Jin, Bo ^a   Huang, Aimi ^a   Bai, Hao ^a   Xiong, Hui ^b   Han, Baohui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Engineering Center of Veterinary Biological Products   (China)

Author keywords

Disease free survival; EGFR mutation; Lung adenocarcinoma; Overall survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER PROGNOSIS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DNA SEQUENCE; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MUTATION; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREDICTIVE VALUE; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY;

EID: 84940305161     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2013.04.02     Document Type: Article

References (19)

1. Chen WQ, Zeng HM, Zheng RS, et al. Cancer incidence and mortality in China, 2007. Chin J Cancer Res, 2012, 24(1): 1-8.
2. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361(10): 947-957.
3. Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol, 2010, 28(5): 744-752.
4. Mak RH, Doran E, Muzikansky A, et al. Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC. Oncologist, 2011, 16(6): 886-895.
5. Koh Y, Jang B, Jeon YK, et al. EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma. Jpn J Clin Oncol, 2011, 41(4): 548-554.
6. Ragusa M, Vannucci J, Ludovini V, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients. Am J Clin Oncol, 2013 Jan 24. [Epub ahead of print]
7. Liu Y, Zhu JQ, Zhang LM, et al. Epithelial growth factor receptor mutation status to the effective of survival in non-small cell lung cancer after surgery. Zhonghua Wai Ke Za Zhi, 2012, 50(12): 1082-1086.
8. Lee YJ, Park IK, Park MS, et al. Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. J Cancer Res Clin Oncol, 2009, 135(12): 1647-1654.
9. Kosaka T, Yatabe Y, Onozato R, et al. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol, 2009, 4(1): 22-29.
10. Liu HP, Isaac Wu HD, Chang JW, et al. Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable nonsmall cell lung cancer in Taiwan. J Thorac Oncol, 2010, 5(8): 1175-1184.
11. Lund-Iversen M, Kleinberg L, Fjellbirkeland L, et al. Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations. J Thorac Oncol, 2012, 7(9): 1471-1473.
12. Chansky K, Sculier JP, Crowley JJ, et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol, 2009, 4(7): 792-801.
13. Kalikaki A, Koutsopoulos A, Hatzidaki D, et al. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer, 2010, 69(1): 110-115.
14. Zhuo ML, Wu MN, Zhao J, et al. Epidermal growth factor receptor genotype in plasma DNA and outcome of chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Chin Med J (Engl), 2011, 124(21): 3510-3514.
15. Li FH, Bai H, Li XN, et al. Role of EGFR mutation status in patients with stage III non-squamous non-small cell lung cancer treated with chemoradiotherapy. Zhongguo Fei Ai Za Zhi, 2011, 14(9): 715-718.
16. Park EA, Lee HJ, Kim YT, et al. EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: investigation of significantly relatedfactors on CT, FDG-PET, and histopathology. Lung Cancer, 2009, 64(2): 179-186.
17. Sasaki H, Shimizu S, Okuda K, et al. Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer. Lung Cancer, 2009, 64(3): 295-300.
18. Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol, 2009, 27(10): 1667-1674.
19. Galleges Ruiz MI, Floor K, Steinberg SM, et al. Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients. Br J Cancer, 2009, 100(1): 145-152.